DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTITHROMBIN-III CONCENTRATES IN SEPTIC SHOCK WITH DISSEMINATED INTRAVASCULAR COAGULATION

被引:277
|
作者
FOURRIER, F
CHOPIN, C
HUART, JJ
RUNGE, I
CARON, C
GOUDEMAND, J
机构
[1] CHRU LILLE,HOP B,HEMATOL LAB,LILLE,FRANCE
[2] CH VALENCIENNES,SERV REANIMAT POLYVALENTE,VALENCIENNES,FRANCE
[3] CTR REG TRANSFUS SANGUINE,LILLE,FRANCE
关键词
D O I
10.1378/chest.104.3.882
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Septic shock is frequently complicated by a syndrome of disseminated intravascular coagulation (DIC). Numerous uncontrolled clinical studies have reported that antithrombin III (ATIII) substitution might prevent DIC and death in septic shock. Methods: We conducted a randomized double-blind placebo-controlled trial in patients with a documented septic shock and DIC. The patients received either a placebo or ATIII (90 to 120 IU/kg in loading dose, then 90 to 120 IU/kg/d during 4 days). Administration of fresh frozen plasma, platelets, and fibrinogen concentrates was restricted to patients with hemorrhages and severe decreases in prothrombin time, platelet count, and fibrinogen levels. Results: Thirty-give patients entered the study (18 placebo, 17 ATIII). Both groups were well balanced for all demographic, hemodynamic, and biologic data. Three patients were excluded before the treatment allocation code was broken. In the ATIII group, ATIII levels were rapidly corrected and remained over normal levels until day 10, sequential protein C and protein S levels were not modified. The duration of DIC was significantly reduced; in the ATIII group, 64 percent of patients were cured of DIC at day 2, and 71 percent were cured at the end of treatment vs in the placebo group, 11 percent (p<0.01) and 33 percent (p<0.05), respectively. In the 32 included patients, the mortality in ICU was reduced by 44 percent in the ATIII group (p=0.22, NS). Care loads and transfusion requirements were not different. No side effect was observed. Conclusions: Mortality was reduced by 44 percent in this trial, but the difference did not reach the statistical significance. Circulating protein C and protein S levels were not modified by ATIII supplementation. High doses of ATIII concentrates significantly improved sepsis-induced DIC during septic shock. The trend toward improved survival suggests further randomized studies.
引用
收藏
页码:882 / 888
页数:7
相关论文
共 50 条
  • [21] EFFICACY OF ANTITHROMBIN-III IN ENDOTOXIN-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION
    HAUPTMAN, JG
    HASSOUNA, HI
    BELL, TG
    PENNER, JA
    EMERSON, TE
    CIRCULATORY SHOCK, 1988, 25 (02) : 111 - 122
  • [22] The use of antithrombin III (ATIII) for disseminated intravascular coagulation (DIC) during septic shock - Reply
    Calori, G
    Baudo, F
    INTENSIVE CARE MEDICINE, 1998, 24 (12) : 1344 - 1344
  • [23] ACUTE DISSEMINATED INTRAVASCULAR COAGULATION ASSOCIATED WITH AMNIOTIC-FLUID EMBOLISM - SUCCESSFUL TREATMENT WITH ANTITHROMBIN-III CONCENTRATES
    MARZI, U
    BORGHESI, L
    PAOLUCCI, R
    PINI, M
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1437 - 1437
  • [24] The cult of the double-blind placebo-controlled trial
    Ellis, SJ
    Adams, RF
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1997, 51 (01): : 36 - 39
  • [25] Antithrombin therapy for severe preeclampsia: Results of a double-blind, randomized, placebo-controlled trial
    Maki, M
    Kobayashi, T
    Terao, T
    Ikenoue, T
    Satoh, K
    Nakabayashi, M
    Sagara, Y
    Kajiwara, Y
    Urata, M
    THROMBOSIS AND HAEMOSTASIS, 2000, 84 (04) : 583 - 590
  • [26] Thiamine as a Renal Protective Agent in Septic Shock A Secondary Analysis of a Randomized, Double-Blind, Placebo-controlled Trial
    Moskowitz, Ari
    Andersen, Lars W.
    Cocchi, Michael N.
    Karlsson, Mathias
    Patel, Parth V.
    Donnino, Michael W.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (05) : 737 - 741
  • [27] Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock
    Stephens, Dianne P.
    Thomas, Jane H.
    Higgins, Alisa
    Bailey, Michael
    Anstey, Nicholas M.
    Currie, Bart J.
    Cheng, Allen C.
    CRITICAL CARE MEDICINE, 2008, 36 (02) : 448 - 454
  • [28] Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery
    Jooste, Edmund H.
    Scholl, Rebecca
    Wu, Yi-Hung
    Jaquiss, Robert D. B.
    Lodge, Andrew J.
    Ames, Warwick A.
    Homi, H. Mayumi
    Machovec, Kelly A.
    Greene, Nathaniel H.
    Donahue, Brian S.
    Shah, Nirmish
    Benkwitz, Claudia
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2019, 33 (02) : 396 - 402
  • [29] Disseminated intravascular coagulation syndromes: Potential management with antithrombin III concentrates - Preface
    Mammen, EF
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 (01): : 1 - 1
  • [30] Antithrombin-III activity associated with disseminated intravascular coagulation in orthotopic liver transplantation
    Haynes, G
    Lazarchick, J
    Palesch, Y
    Harvey, S
    Baliga, P
    ANESTHESIOLOGY, 1998, 89 (3A) : U346 - U346